Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 in HER2-positive Advanced Breast Cancer Post T-DXd
NCT06578286Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
01
Overview
A Phase 2 trial of anvatabart opadotin in breast cancer, sponsored by Fudan University. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
anvatabart opadotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06578286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578286.